IL286713B2 - Liposomal formulations and methods for using and preparing them - Google Patents

Liposomal formulations and methods for using and preparing them

Info

Publication number
IL286713B2
IL286713B2 IL286713A IL28671321A IL286713B2 IL 286713 B2 IL286713 B2 IL 286713B2 IL 286713 A IL286713 A IL 286713A IL 28671321 A IL28671321 A IL 28671321A IL 286713 B2 IL286713 B2 IL 286713B2
Authority
IL
Israel
Prior art keywords
composition
molar percent
salt
liposome
phospholipid
Prior art date
Application number
IL286713A
Other languages
English (en)
Hebrew (he)
Other versions
IL286713A (en
IL286713B1 (en
Original Assignee
Glycomine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomine Inc filed Critical Glycomine Inc
Publication of IL286713A publication Critical patent/IL286713A/en
Publication of IL286713B1 publication Critical patent/IL286713B1/en
Publication of IL286713B2 publication Critical patent/IL286713B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL286713A 2019-03-29 2020-03-27 Liposomal formulations and methods for using and preparing them IL286713B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962826874P 2019-03-29 2019-03-29
PCT/US2020/025246 WO2020205530A1 (en) 2019-03-29 2020-03-27 Liposomal formulations, and methods of using and preparing thereof

Publications (3)

Publication Number Publication Date
IL286713A IL286713A (en) 2021-10-31
IL286713B1 IL286713B1 (en) 2025-03-01
IL286713B2 true IL286713B2 (en) 2025-07-01

Family

ID=72666933

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286713A IL286713B2 (en) 2019-03-29 2020-03-27 Liposomal formulations and methods for using and preparing them

Country Status (19)

Country Link
US (1) US20220184107A1 (enExample)
EP (1) EP3946365A4 (enExample)
JP (1) JP7583741B2 (enExample)
KR (1) KR20210143906A (enExample)
CN (1) CN113873998A (enExample)
AR (1) AR119705A1 (enExample)
AU (1) AU2020252005B2 (enExample)
BR (1) BR112021019593A2 (enExample)
CA (1) CA3134828A1 (enExample)
CL (1) CL2021002512A1 (enExample)
CO (1) CO2021014274A2 (enExample)
EA (1) EA202192663A1 (enExample)
IL (1) IL286713B2 (enExample)
MX (1) MX2021011876A (enExample)
PE (1) PE20212366A1 (enExample)
PH (1) PH12021552428A1 (enExample)
SG (1) SG11202110623PA (enExample)
TW (1) TWI906214B (enExample)
WO (1) WO2020205530A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205628A1 (en) * 2022-04-18 2023-10-26 City Of Hope Lipid nanoparticles, nucleic acids, and methods of use
TW202543582A (zh) * 2024-02-29 2025-11-16 美商葛里柯麥公司 脂質體調配物及其使用及製備方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110014272A1 (en) * 2009-05-14 2011-01-20 Sanofi Pasteur Method for adjuvanting lipopolysaccharide (LPS) of Gram-negative bacteria
US20160228364A1 (en) * 2013-09-16 2016-08-11 Glycomine, Inc. Pharmaceutical preparation of carbohydrates for therapeutic use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156783B1 (en) * 1999-03-02 2007-10-24 Transave, Inc. Encapsulation of bioactive complexes in liposomes
US7060291B1 (en) * 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
WO2002076428A1 (en) * 2001-03-26 2002-10-03 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
AU2003205048B2 (en) * 2002-01-09 2009-02-26 Transave, Inc. Efficient liposomal encapsulation
WO2003059322A1 (en) * 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
MX366055B (es) 2011-08-31 2019-06-26 Novartis Ag Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
CA2890725A1 (en) 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
JP2017537650A (ja) 2014-10-09 2017-12-21 ライポテック・ピーティーワイ・リミテッド キメラタンパク質
US20170165374A1 (en) * 2015-11-18 2017-06-15 Insmed, Inc. Compositions and methods for treating bacterial infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110014272A1 (en) * 2009-05-14 2011-01-20 Sanofi Pasteur Method for adjuvanting lipopolysaccharide (LPS) of Gram-negative bacteria
US20160228364A1 (en) * 2013-09-16 2016-08-11 Glycomine, Inc. Pharmaceutical preparation of carbohydrates for therapeutic use

Also Published As

Publication number Publication date
EP3946365A4 (en) 2023-04-19
SG11202110623PA (en) 2021-10-28
CN113873998A (zh) 2021-12-31
AU2020252005A1 (en) 2021-11-04
JP2022527638A (ja) 2022-06-02
MX2021011876A (es) 2022-01-04
AR119705A1 (es) 2022-01-05
CL2021002512A1 (es) 2023-01-06
KR20210143906A (ko) 2021-11-29
AU2020252005B2 (en) 2025-11-27
CA3134828A1 (en) 2020-10-08
EP3946365A1 (en) 2022-02-09
JP7583741B2 (ja) 2024-11-14
EA202192663A1 (ru) 2022-03-01
TWI906214B (zh) 2025-12-01
US20220184107A1 (en) 2022-06-16
WO2020205530A1 (en) 2020-10-08
IL286713A (en) 2021-10-31
IL286713B1 (en) 2025-03-01
PE20212366A1 (es) 2021-12-21
BR112021019593A2 (pt) 2021-12-14
TW202102231A (zh) 2021-01-16
CO2021014274A2 (es) 2022-01-17
PH12021552428A1 (en) 2022-07-11

Similar Documents

Publication Publication Date Title
US20240082155A1 (en) Pharmaceutical preparation of carbohydrates for therapeutic use
IL310719A (en) Recombinant human acid alpha-glucosidase
IL286713B2 (en) Liposomal formulations and methods for using and preparing them
IL256662A (en) Focusidase inhibitors
IL314191A (en) An ionizable lipid containing an ester bond that breaks down naturally and lipid nanoparticles containing it
JPWO2014025042A1 (ja) 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
IL273988B2 (en) Cannabidiol and chitosan compositions and methods of using the same
IL301088A (en) Ribitol treatment
IL296221A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
EA050120B1 (ru) Липосомальные фармацевтические композиции и способ их применения
US20240115502A1 (en) Liposomes and its use for enzyme delivery
US20240325327A1 (en) Method for attenuating neuroinflammation, amyloidopathy and tauopathy
CN1679957B (zh) 含脂质体的癌症治疗用药物组合物
HK40102572B (zh) 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法
HK40102572A (zh) 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法
Qin et al. Elucidating structure of endogenous phospholipids on in vivo absorption of octreotide following lung administration
HK40128812A (zh) 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法
WO2020061670A1 (pt) Formulação lipossomal, composição farmacêutica, uso de uma formulação lipossomal, método para tratamento de câncer, e, processo para preparação de uma formulação lipossomal